An aptamer targeting shared tumor-specific peptide antigen of MAGE-A3 in multiple cancers

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The MAGE-A3 (melanoma antigen gene A3) protein is a tumor-specific antigen expressed in various cancers.
• Targeting tumor-specific antigens is a key strategy in cancer therapy and diagnostics.
• Developing specific and sensitive targeting agents is crucial for effective cancer management.

Purpose of the Study:

• To identify and characterize a DNA aptamer targeting the MAGE-A3111-125 peptide.
• To evaluate the aptamer's binding affinity and specificity to cancer cells.
• To explore the potential of this aptamer in cancer cell targeting and diagnosis.

Main Methods:

• Selection and characterization of a DNA aptamer against the MAGE-A3111-125 peptide.
• Measurement of aptamer-peptide dissociation constant (Kd) using biophysical techniques.
• Confirmation of aptamer binding to cancer cells via flow cytometry and fluorescence imaging.
• Utilizing Cy3-conjugated aptamers for signal detection and localization.

Main Results:

• A DNA aptamer with a dissociation constant of 57 nM was identified against the MAGE-A3111-125 peptide.
• The aptamer demonstrated specific binding to seven types of cancer cells: melanoma, breast, colorectal, liver, lung, pancreas, and oral cancer.
• Fluorescence imaging confirmed specific localization of the aptamer to the surface of these cancer cells.

Conclusions:

• The identified DNA aptamer effectively targets the MAGE-A3 peptide on multiple cancer types.
• This aptamer holds significant potential for developing novel cancer cell targeting strategies.
• The findings suggest a promising new modality for the diagnosis of various cancers.